timing of high-efficacy disease modifying therapies for relapsing-remitting multiple sclerosis

Conclusions
Early commencement of high-efficacy DMTs in relapsing-remitting multiple sclerosis provides superior control over relapse activity than their delayed commencement. However, disability outcomes on high-efficacy DMTs are independent of the timing of therapy.

Source: Journal of Neurology, Neurosurgery and Psychiatry - May 8, 2017 Category: Neurosurgery Authors: Merkel, B., Jokubaitis, V., Spelman, T., Lechner-Scott, J., McCombe, P., Slee, M., Vucic, S., Skibina, O., Barnett, M., Hodgkinson, S., Butzkueven, H., Kalincik, T. Tags: Abstracts Source Type: research